“…In clinical. trials Cahill, Hill, Jessop, and Kendall (1965), Barnardo, Currey, Mason, Fox, and Weatherall (1966), and Myles, Bacon, and Williams (1967) have suggested that it is of comparable value to aspirin and phenylbutazone, but has a very low incidence of upper intestinal side-effects, which are common with the majority of drugs used in chronic rheumatic diseases. In view of the pogsible relation between mefenamic acid and haemolytic anaemia long-term therapy with this drug should be undertaken with caution and the patients should be watched carefully for evidence of haemolysis.…”